Immune Response Profiling

Characterize immune dysfunction with the HTG EdgeSeq Immune Response Panel for targeted, high-throughput gene expression profiling

immune system dysfunction in
immune response disease 

The HTG EdgeSeq Immune Response Panel leverages the sensitivity and dynamic range of next-generation sequencing (NGS) to measure expression levels of 2,002 genes implicated in a variety of autoimmune diseases.

This panel was designed to provide critical insight into the following applications:

  • Evaluate pathways, processes, and cell types involved in autoimmune disease, chronic inflammatory disease, and abnormal immune response
  • Elucidate therapeutic mechanism of action or validate drug targets
  • Measure immunotherapy induced responses
  • Discover and validate disease- and therapeutic- specific biomarkers
  • Develop predictive signatures of drug response

Therapeutic Categories

  • Type I interferon
  • Type II interferon
  • Innate and adaptive immune-related interleukins
  • Tumor necrosis factor (TNF)
  • Toll-like receptors
  • Immune cell signaling
  • Immune checkpoint and co-stimulatory targets
  • Other immunomodulatory agents

Disease-Specific Profiling

  • Rheumatoid arthritis
  • Type 1 diabetes
  • Systemic lupus erythematosus
  • Ankylosing spondylitis
  • Crohn’s disease
  • Ulcerative colitis
  • Irritable bowel syndrome
  • Multiple sclerosis
  • Psoriasis

Assay Validation Report

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit.
  • Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
HTG EdgeSeq Autoimmune Panel Validation Report

Autoimmune Profiling Supports The Drug Development Lifecycle

The HTG EdgeSeq Autoimmune Panel can be used to evaluate pathways, processes, and cell types involved in autoimmune disease, chronic inflammatory disease, and abnormal immune response.

Biomarker discovery

Discovery & validation of disease and therapeutic- specific biomarkers

Drug development

Target validation and therapeutic mechanism of action studies

Clinical trial monitoring

Immunotherapy induced response event investigations

CDx development

Investigation of predictive signatures of drug response & IVD assay development

See Autoimmune Gene Expression Profiling In Action. Download The Case Studies

Translational Applications In Autoimmune (AI)
And Immuno-oncology (IO)

Patient Stratification

  • Biomarkers differentiate AI patients from healthy controls1
  • RNA signatures reveal distinct subsets of AI patients2
  • Patients with high vs low disease activity cluster according to biomarker expression3

Treatment Responses

  • Certain biomarkers correlate with improved response to AI treatment4
  • Patients with IO-induced AI symptoms have RNA signatures related to AI patients5
  • RNA signatures can potentially be used to predict IO and AI treatment response6,7

Mechanism of Action 

  • Biomarkers could help discover the MOA in patients with adverse responses to AI or IO therapy
  • Unique biomarker signatures in patients that do not respond to treatments could be further investigated to identify new drug targets
Normalization and principal component analysis tools: